<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium channel blockers in the treatment of cardiac arrhythmias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium channel blockers in the treatment of cardiac arrhythmias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Calcium channel blockers in the treatment of cardiac arrhythmias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher Madias, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Calcium channel blockers (CCBs) are useful antiarrhythmic agents in the management of certain arrhythmias, primarily supraventricular tachyarrhythmias [<a href="#rid1">1-3</a>]. They have diverse electrophysiologic properties and are therefore of variable antiarrhythmic efficacy. The primary settings in which they are useful can be best appreciated from an understanding of their mechanism of action.</p><p>This topic will review the electrophysiological properties of CCBs and their clinical indications in a variety of arrhythmias. More detailed discussions of the use of CCBs in specific arrhythmias, CCBs for nonarrhythmic conditions, and other treatment options for arrhythmias are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1471.html" rel="external">"Calcium channel blockers in the management of chronic coronary syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3455.html" rel="external">"Calcium channel blockers in heart failure with reduced ejection fraction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/101641.html" rel="external">"Wide QRS complex tachycardias: Approach to management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">ELECTROPHYSIOLOGIC PROPERTIES</span><span class="headingEndMark"> — </span>CCBs, considered class IV antiarrhythmic drugs  (<a class="graphic graphic_table graphicRef120433" href="/d/graphic/120433.html" rel="external">table 1</a>), preferentially affect myocardial tissue with a slow action potential that is mediated by calcium currents. The sinoatrial and atrioventricular nodes depend on calcium currents to generate slowly propagating action potentials. In contrast, fast response myocardial tissues (the atria, specialized infranodal conducting system, the ventricles, and accessory pathways) depend on sodium channel currents. (See  <a class="medical medical_review" href="/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"</a>.)</p><p>CCBs block the slow calcium channel in a dose-dependent fashion, resulting in the following direct effects [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Slowing of phase 4 depolarization and the conduction velocity of the sinoatrial (SA) and atrioventricular (AV) nodes</p><p class="bulletIndent1"><span class="glyph">●</span>Lengthening the antegrade and retrograde refractory periods of the AV node</p><p class="bulletIndent1"><span class="glyph">●</span>Slowing of the sinus rate and increased PR interval on the electrocardiogram (ECG) via the slowing of conduction through the AV node</p><p></p><p>Similar to sodium channel blockers, CCBs with antiarrhythmic activity (ie, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) exhibit "use-dependence." This phenomenon is characterized by an increase in the extent of calcium channel blockade as the frequency of impulse generation and ventricular activation increases. CCBs can also cause significant peripheral vasodilation, an effect which can induce reflex activation of the sympathetic nervous system. As a result, the observed electropharmacologic and pharmacodynamic properties of CCBs represent a combination of direct effects and indirect sympathetic reflex actions. This is particularly important with dihydropyridines (ie, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>), which are potent vasodilators and sympathetic activators. The serum concentration of dihydropyridine CCBs necessary to achieve electrophysiologic activity in humans is much higher than the concentration needed to induce potent vasodilation. Therefore, at prescribed doses, these agents do not exert measurable electrophysiologic effects and appear to be devoid of antiarrhythmic activity. In addition, the reflex activation of the sympathetic nervous system offsets any direct effect of the dihydropyridine CCBs on the sinoatrial and AV nodes. </p><p>Among nondihydropyridine CCBs, the effect on vasodilation is more apparent with <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> than <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, which results in verapamil having a more pronounced effect on the SA and AV nodes as its action is not offset by vasodilatory activation of sympathetic activity.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>Because <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> primarily affect slow response tissues in the SA and AV nodes, these medications are primarily used for the management of supraventricular tachycardias dependent on conduction through the AV node (ie, atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia) and for ventricular rate control in atrial fibrillation (AF), atrial flutter, and atrial tachycardia. They are largely ineffective for the direct prevention of most ventricular arrhythmias; however, there are some exceptions, such as the utility of verapamil for the treatment of idiopathic fascicular ventricular tachycardia. (See <a class="local">'Ventricular arrhythmia'</a> below.)</p><p>The antiarrhythmic effect of <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> appears to be similar in adults and children, although less experience is available in children [<a href="#rid1">1,2,5</a>]. Verapamil and to a lesser degree <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> may be harmful in patients with hypotension or impaired ventricular function (especially those with a history of heart failure [HF]), and in general should not be used in patients with these conditions. In addition, CCBs should be used cautiously in patients already taking a beta blocker because of the combined negative inotropic and chronotropic effects of both classes of medications [<a href="#rid5">5</a>].</p><p>A brief review of these issues is provided here; the use of CCBs in the treatment of specific arrhythmias is discussed in detail elsewhere.</p><p class="headingAnchor" id="H4"><span class="h2">Supraventricular tachycardia</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> are accepted as treatments of choice for the termination of supraventricular tachycardias (SVT), such as AV nodal reentrant tachycardia and atrioventricular reciprocating tachycardia due to an accessory pathway. An important exception to the first-line use of these agents occurs in unstable patients with hemodynamic compromise. In an unstable patient with SVT, the preferred treatment is direct electrical cardioversion or intravenous <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>, a very short-acting AV nodal blocking agent that rarely produces additional hypotension. (See  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p>Another situation in which CCBs should be avoided or used with caution is in the presence of a wide QRS complex tachycardia. If there is no doubt that a wide QRS complex tachycardia is supraventricular in origin, therapy directed at the AV node and the SVT may be given. In such cases, management is similar to that described above for SVT with a normal QRS duration. However, with a wide QRS complex tachycardia that is potentially ventricular tachycardia, CCBs blockers should be avoided, as there is a risk for hemodynamic deterioration following the administration of these medications. (See  <a class="medical medical_review" href="/d/html/101641.html" rel="external">"Wide QRS complex tachycardias: Approach to management"</a>.)</p><p>CCBs appear to be of limited value in other forms of reentrant and automatic SVT [<a href="#rid2">2,3,5,6</a>]. Limited data exist concerning their role in SA nodal reentrant tachycardia or in atrial tachycardia due to an ectopic focus or intraatrial reentry (except for rate control by AV nodal blockade). However, oral <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> may convert paroxysmal atrial tachycardia with block to sinus rhythm under certain circumstances, such as <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> toxicity.</p><p class="headingAnchor" id="H5"><span class="h2">Multifocal atrial tachycardia</span><span class="headingEndMark"> — </span>Either a non-dihydropyridine calcium channel blocker (ie, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) or a beta blocker is usually the treatment of choice for multifocal atrial tachycardia. These drugs impair AV nodal conduction and will therefore slow the ventricular rate in this disorder; they do not usually reverse or prevent this arrhythmia. (See  <a class="medical medical_review" href="/d/html/901.html" rel="external">"Multifocal atrial tachycardia"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Atrial fibrillation and flutter</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> are used both acutely (via the intravenous route) and chronically (via the oral route) to slow the ventricular response in AF and atrial flutter. Their efficacy for rate control is due to their direct action to slow conduction and prolonged refractoriness in the AV node. Verapamil and diltiazem reduce both the resting and the exercise-induced increases in heart rate, whereas the major effect of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> (which works on the AV node via enhancing vagal tone) is on the resting rate. Therefore, verapamil and diltiazem are generally preferred to digoxin as monotherapy (in the absence of underlying HF) [<a href="#rid7">7</a>]. However, for patients with inadequate ventricular rate control with monotherapy, the concurrent use of digoxin or a beta blocker with verapamil or diltiazem has an additive depressant effect on the AV node. (See  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a> and  <a class="medical medical_review" href="/d/html/1067.html" rel="external">"Control of ventricular rate in atrial flutter"</a>.)</p><p>AV nodal blocking medications that are normally used to control the ventricular rate during AF (most importantly) or atrial flutter, including the CCBs <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, are contraindicated in patients with an accessory pathway and preexcitation. This is discussed in further detail in another topic. (See  <a class="medical medical_review" href="/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'When to avoid AV nodal blockers'</a>.)</p><p>CCBs also have a propensity to convert atrial flutter to fibrillation in a small number of patients, presumably due to a shortening of the atrial effective refractory period [<a href="#rid8">8</a>]. CCBs have been regarded as having little value in the termination and prevention of AF. However, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> may prevent the atrial electrical remodeling that occurs in AF, and the combination of verapamil with another agent has been shown to be effective in preventing AF recurrence [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Verapamil'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Ventricular arrhythmia</span><span class="headingEndMark"> — </span>The role of CCBs in ventricular arrhythmias is less well defined [<a href="#rid10">10-15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>CCBs inadequately suppress ventricular premature beats in patients with structurally normal or abnormal hearts. They also have no significant effect on arrhythmia frequency or arrhythmic mortality in patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, or mitral valve prolapse [<a href="#rid1">1,2,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a class, CCBs have a limited role in the treatment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in the setting of organic heart disease. They do not suppress nonsustained VT, nor do they prevent the inducibility of VT/VF after programmed electrical stimulation. (See  <a class="medical medical_review" href="/d/html/917.html" rel="external">"Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management"</a>.)</p><p></p><p>However, calcium blockers may have a role in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>They are often effective when ventricular tachycardia or fibrillation is due to transient coronary artery spasm [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>They may have a role for polymorphic VT in the structurally normal heart or in those with familial catecholaminergic polymorphic VT that is due to a RyR2 or calsequestrin gene mutation [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/916.html" rel="external">"Catecholaminergic polymorphic ventricular tachycardia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exercise-triggered VT (called repetitive monomorphic VT) having the morphologic pattern of left bundle branch block and an inferiorly directed axis deviation (right ventricular outflow tract tachycardia) or a pattern of right bundle branch block and rightward axis (left ventricular outflow tract tachycardia) may respond predictably and promptly to intravenous <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>. Such an arrhythmia may occur in patients without identifiable cardiac disease [<a href="#rid12">12,19,20</a>]. (See  <a class="medical medical_review" href="/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A relatively rare, sustained VT that occurs in patients without evidence of structural heart disease has the morphologic pattern of right bundle branch block with left axis deviation [<a href="#rid21">21-23</a>]. This arrhythmia, which is called an idiopathic fascicular ventricular tachycardia (primarily of the left posterior fascicle), <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> sensitive tachycardia, or Belhassen tachycardia, appears to be a distinct clinical entity and, in most cases, responds to intravenous verapamil [<a href="#rid21">21,24</a>]. (See  <a class="medical medical_review" href="/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Arrhythmia mortality after myocardial infarction</span><span class="headingEndMark"> — </span>Routine treatment of the post-MI patient with a calcium channel blocker is not justified. It is possible that CCBs might benefit selected patients after MI, particularly those with a non-Q wave infarct, without HF, and who are unable to take a beta blocker [<a href="#rid25">25-27</a>]. However, the level of benefit, if present, is small. Additionally, there are subsets of patients in whom certain CCBs may increase mortality (see  <a class="medical medical_review" href="/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Calcium channel blockers'</a> and  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a> and  <a class="medical medical_review" href="/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction", section on 'Calcium channel blockers'</a>). </p><p>CCBs reverse coronary vasospasm and attenuate myocardial ischemic damage following experimental coronary occlusion [<a href="#rid28">28</a>]. These observations led to clinical studies assessing if these drugs might increase survival in patients with acute myocardial infarction (MI). </p><p>Numerous randomized controlled trials of CCBs (<a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, and <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>) have been analyzed [<a href="#rid29">29,30</a>]. No agent was found to unequivocally and decisively decrease mortality; in fact, pooled data for five CCBs suggested an unfavorable trend in total mortality, particularly with the short-acting dihydropyridines  (<a class="graphic graphic_figure graphicRef74199" href="/d/graphic/74199.html" rel="external">figure 1</a>). This is in contrast to the clear benefit associated with other drugs such as beta blockers, statins, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, and angiotensin converting enzyme inhibitors. (See  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a>.)</p><p class="headingAnchor" id="H1428150565"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H8318644"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>, the calcium channel blockers (CCBs) <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> are treatments of choice for the termination of supraventricular tachycardia. (See <a class="local">'Supraventricular tachycardia'</a> above and  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">Diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> can be used both acutely (via the intravenous route) and chronically (via the oral route) to slow the ventricular response in atrial fibrillation (AF), atrial tachycardia, and atrial flutter. (See <a class="local">'Atrial fibrillation and flutter'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with hypotension or impaired ventricular function, especially those with a history of heart failure, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> may be harmful, and are relatively contraindicated. (See <a class="local">'Clinical use'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CCBs should be used cautiously in patients already taking a beta blocker because of the combined negative inotropic and chronotropic effects of both classes of medications. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with a wide QRS complex tachycardia that is potentially ventricular tachycardia, CCBs should be <strong>avoided</strong>, as there is a risk for hemodynamic deterioration following the administration of these medications. (See <a class="local">'Supraventricular tachycardia'</a> above and  <a class="medical medical_review" href="/d/html/101641.html" rel="external">"Wide QRS complex tachycardias: Approach to management"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haines DE, DiMarco JP. Current therapy for supraventricular tachycardia. Curr Probl Cardiol 1992; 17:411.</a></li><li><a class="nounderline abstract_t">Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. Drugs 1978; 15:169.</a></li><li><a class="nounderline abstract_t">Singh BN, Hecht HS, Nademanee K, Chew CY. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis 1982; 25:103.</a></li><li><a class="nounderline abstract_t">Cranefield PF, Aronson RS, Wit AL. Effect of verapamil on the noraml action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circ Res 1974; 34:204.</a></li><li><a class="nounderline abstract_t">Singh BN, Nademanee K, Baky SH. Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs 1983; 25:125.</a></li><li><a class="nounderline abstract_t">Boriani G, Bertaglia E, Carboni A, et al. A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. Int J Cardiol 2005; 104:73.</a></li><li><a class="nounderline abstract_t">Tsuneda T, Yamashita T, Fukunami M, et al. Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J 2006; 70:965.</a></li><li class="breakAll">Singh BN. Control of cardiac arrhythmias by modulation of the slow myocardial channel. In: Calcium channels, their properties, functions, regulation, and clinical relevance, Horowitz L, Partridge LD, Leach JK (Eds), CRC Press, Boca Raton 1991. p.327.</li><li><a class="nounderline abstract_t">De Simone A, De Pasquale M, De Matteis C, et al. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24:1425.</a></li><li><a class="nounderline abstract_t">Belhassen B, Horowitz LN. Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol 1984; 54:1131.</a></li><li><a class="nounderline abstract_t">Wellens HJ, Bär FW, Lie KI, et al. Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. Am J Cardiol 1977; 40:579.</a></li><li><a class="nounderline abstract_t">Gill JS, Blaszyk K, Ward DE, Camm AJ. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 1993; 126:1126.</a></li><li><a class="nounderline abstract_t">Sung RJ, Shapiro WA, Shen EN, et al. Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity, and triggered activity. J Clin Invest 1983; 72:350.</a></li><li><a class="nounderline abstract_t">Sclarovsky S, Strasberg B, Fuchs J, et al. Multiform accelerated idioventricular rhythm in acute myocardial infarction: electrocardiographic characteristics and response to verapamil. Am J Cardiol 1983; 52:43.</a></li><li><a class="nounderline abstract_t">Grenadier E, Alpan G, Maor N, et al. Polymorphous ventricular tachycardia in acute myocardial infarction. Am J Cardiol 1984; 53:1280.</a></li><li><a class="nounderline abstract_t">McKenna, WJ, Harris, et al. Hypertrophic cardiomyopathy: Comparison of verapamil and amiodarone in the treatment of arrhythmia. Br Heart J 1980; 45:354.</a></li><li><a class="nounderline abstract_t">Kimura E, Tanaka K, Mizuno K, et al. Suppression of repeatedly occurring ventricular fibrillation with nifedipine in variant form of angina pectoris. Jpn Heart J 1977; 18:736.</a></li><li><a class="nounderline abstract_t">Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005; 16:162.</a></li><li><a class="nounderline abstract_t">Palileo EV, Ashley WW, Swiryn S, et al. Exercise provocable right ventricular outflow tract tachycardia. Am Heart J 1982; 104:185.</a></li><li><a class="nounderline abstract_t">Wu D, Kou HC, Hung JS. Exercise-triggered paroxysmal ventricular tachycardia. A repetitive rhythmic activity possibly related to afterdepolarization. Ann Intern Med 1981; 95:410.</a></li><li><a class="nounderline abstract_t">Lin FC, Finley CD, Rahimtoola SH, Wu D. Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties. Am J Cardiol 1983; 52:95.</a></li><li><a class="nounderline abstract_t">German LD, Packer DL, Bardy GH, Gallagher JJ. Ventricular tachycardia induced by atrial stimulation in patients without symptomatic cardiac disease. Am J Cardiol 1983; 52:1202.</a></li><li><a class="nounderline abstract_t">Belhassen B, Shapira I, Pelleg A, et al. Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECG-electrophysiologic entity. Am Heart J 1984; 108:1034.</a></li><li><a class="nounderline abstract_t">Nogami A. Idiopathic left ventricular tachycardia: assessment and treatment. Card Electrophysiol Rev 2002; 6:448.</a></li><li><a class="nounderline abstract_t">Verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984; 5:516.</a></li><li><a class="nounderline abstract_t">Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol 1990; 66:779.</a></li><li><a class="nounderline abstract_t">Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385.</a></li><li class="breakAll">Singh BN, Nayler WG. The role of calcium antagonists in acute myocardial infarction. In: Early interventions in acute myocardial infarction, Rapaport E (Ed), Kluwer Academic Publications, Boston 1989. p.123.</li><li class="breakAll">Held PH, Yusuf S. Impact of calcium channel blockers on mortality. In: Cardiovascular pharmacology and therapeutics, Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL (Eds), Churchill Livingtion, New York 1993. p.525.</li><li><a class="nounderline abstract_t">Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67:1295.</a></li></ol></div><div id="topicVersionRevision">Topic 951 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1606844" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current therapy for supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/346345" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Verapamil: a review of its pharmacological properties and therapeutic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7051136" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Electrophysiologic and hemodynamic effects of slow-channel blocking drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4811074" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of verapamil on the noraml action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339197" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Calcium antagonists. Clinical use in the treatment of arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16137513" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864926" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864926" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909071" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6496334" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of intravenous verapamil for ventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/910721" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8237755" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6874951" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity, and triggered activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6858925" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multiform accelerated idioventricular rhythm in acute myocardial infarction: electrocardiographic characteristics and response to verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6711428" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Polymorphous ventricular tachycardia in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertrophic cardiomyopathy: Comparison of verapamil and amiodarone in the treatment of arrhythmia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/926318" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Suppression of repeatedly occurring ventricular fibrillation with nifedipine in variant form of angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720454" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6213141" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Exercise provocable right ventricular outflow tract tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7283291" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Exercise-triggered paroxysmal ventricular tachycardia. A repetitive rhythmic activity possibly related to afterdepolarization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6858937" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650408" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ventricular tachycardia induced by atrial stimulation in patients without symptomatic cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6485983" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECG-electrophysiologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438827" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Idiopathic left ventricular tachycardia: assessment and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6383832" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220572" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899840" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of diltiazem on mortality and reinfarction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899840" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effect of diltiazem on mortality and reinfarction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899840" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effect of diltiazem on mortality and reinfarction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035457" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
